Project Grant R44GM119873

The National Science Foundation (NSF) awarded a $550,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program to the University of California, Los Angeles (UCLA) to develop a rapid, multiplexed diagnostic tool for serological testing of tick-borne diseases (TBDs). This 2-year project seeks to improve blood-based detection of TBDs, including Lyme disease, Babesia, Anaplasma, and relapsing fever, through an innovative point-of-care (POC) serological assay. The goal is...

L2 Diagnostics LLC received a $293,142 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 21, 2025, with a completion date of August 31, 2027. The award supports development of a rapid diagnostic test (RDT) in lateral flow assay (LFA) format for detecting Babesia microti infection. The test targets BMGPI12 (BMSA1), a secreted protein released into the...

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,857,470 Cooperative Agreement to The Geneva Foundation to develop a multiplex testing platform that can simultaneously detect and identify Plasmodium species infections. This platform will serve as both a diagnostic tool and an epidemiological surveillance tool. The project performance period is from June 1, 2024 to May 31, 2028. Under a $268,312 sub-award, Meso Scale...

Project Grant Award Summary Antigen Discovery Inc. (also operating as Immport Therapeutics Inc.) received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of August 25, 2025, and completion date of July 31, 2027. The project deliverables focus on developing a sensitive and specific serological potency test (PSPT) for whole cell pertussis vaccines to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

Federal Cooperative Agreement Summary Prompt Diagnostics, Inc. received a $1.25M Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded June 15, 2025, with completion targeted for May 31, 2027. The company is developing an automated, multiplexed point-of-care diagnostic platform for rapid detection and quantification of Treponema pallidum infections (syphilis). The solution integrates magnetic...

The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) awarded a $143,072 Cooperative Agreement under the Plant and Animal Disease, Pest Control, and Animal Care Federal Grant Program (CFDA 10.025) to the Regents of the University of California at Riverside. The primary purpose of this agreement is to consolidate 10 singleplex real-time PCR (qPCR) assays currently used by the California Citrus Clonal Protection Program (CCPP) into three multiplex qPCR assays, and...

This federal Project Grant award of $1,176,645.00, granted by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a highly accurate proteomic diagnostic assay to identify active Borreliosis (Lyme disease) infection with point-of-need collection technology. The grant recipient, George Mason University, will conduct this research in collaboration with a subcontract to The Johns Hopkins University, which will provide...

Controlpoint Inc. was awarded a $256,000 Project Grant from the National Science Foundation to develop a rapid, single-use, point-of-care lateral flow device for detecting kennel cough pathogens. The one-year award, made under the NSF Technology, Innovation, and Partnerships program, will support test validation, prototype manufacturing, and clinical evaluation to demonstrate the feasibility of detecting multiple bacteria and viruses associated with kennel cough in a single diagnostic test....

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $238,500 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, San Diego (UCSD) to develop a novel electrochemical lateral flow assay (ELFA) for diagnosing tuberculosis (TB) from a single drop of blood. The objective is to create a highly sensitive and specific point-of-need TB detection test that can accurately distinguish active TB from...